With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its standard processes and procedures are as streamlined and effective as possible.
Conventional two-dimensional (2D) cell models (adherent cells grown on cell culture plates or cells in suspension) are limited in their abilities to accurately predict clinical toxicity since they lack the fundamental complexity of in vivo tissue environments.
The pharmaceutical industry is facing ever-growing difficulties in developing new drugs and bringing them to market1,2. Many factors stand in the way of R&D productivity, not least of which are shrinking budgets. Yet one of the most pressing challenges continues to be the issue of ensuring that new drug candidates have an acceptable safety profile.
The rapidly escalating costs of drug development is causing the biopharmaceutical industry to focus its R&D efforts on identifying new technologies and methods that can predict the safety and efficacy of new compounds as early as possible in the drug development process. Today, only one in 11 compounds advance from first-in-man studies to regulatory approval and these late-stage failures (mainly caused by safety issues) exact a heavy toll on the biopharmaceutical industry as the cost of clinical trials is extremely expensive, legal liability is of concern and companies are under great scrutiny by investors
The BlueScreen HCTM genotoxicity assay from Gentronix Ltd. uses a human-derived, p53-competent, TK6 cell line to host a luminescence-based reporter system that exploits the proper regulation of the GADD45a gene. GADD45a plays an important role in mediating the cellular response to genotoxic stress.
Metabonomics can offer one of the most complete solutions to tackling one of the pharmaceutical industry's biggest problems attrition. This article discusses the scope and uses of metabonomics in different areas of the drug discovery and development process.
Human beings are complex gene machines that rely on the intricate interplay of ~25,000 genes to impart biological function. Genomic function is affected by genetic variability and environmental factors, giving rise to considerable functional heterogeneity in the human population. Drug responsiveness and side-effects can vary from person to person, as seen in the recent observation of COX-2 inhibitor toxicity in a subset of prescribed users.
Key Features • Automated image acquisition using the Operetta™ High Content Screening System • Data analysis using the versatile Harmony™ Software • Image-based quantification of drug induced cytotoxic effects on hepatocytes
Key Features • Automated confocal image acquisition of live cells using the Opera™ High Content Screening system • Image analysis using Acapella™ LiveDead Script and CellRegionAnalysis Script • Quantification of characteristic changes following a toxic insult
Amyloid-related toxicity need not necessarily be the inevitable consequence of ageing, if some of the new drug discovery strategies to treat neurodegenerative and other ageing-related diseases succeed in the clinic.